Skip to Content

TIMOLOL EYE DROPS 0.5%

Active substance(s): TIMOLOL MALEATE / TIMOLOL MALEATE

View full screen / Print PDF » Download PDF ⇩
Transcript
SUMMARY OF PRODUCT CHARACTERISTICS

1

NAME OF THE MEDICINAL PRODUCT
Timolol Eye Drops 0.5%

2

QUALITATIVE AND QUANTITATIVE COMPOSITION
Active Ingredient
Timolol

5.0 mg/ml

(as Timolol maleate

3

6.8 mg/ml)

PHARMACEUTICAL FORM
Eye drops, solution.

4.

CLINICAL PARTICULARS

4.1

Therapeutic indications
Reduction of elevated intraocular pressure in conditions such as:
-

4.2.

Ocular hypertension;
Chronic open-angle glaucoma (including aphakic patients);
Some cases of secondary glaucoma

Posology and method of administration
Adults and children over 12 years: recommended therapy is one drop of
Timolol Eye Drops in the affected eye(s) twice a day.
Elderly: Dosage need not be modified for the elderly as there has been wide
experience with the use of Timolol Eye Drops in elderly patients.

When using nasolacrimal occlusion or closing the eyelids for 2 minutes, the
systemic absorption is reduced. This may result in a decrease in systemic side
effects and an increase in local activity.
Intraocular pressure should be reassessed approximately four weeks after
starting treatment because response to Timolol Eye Drops may take a few
weeks to stabilise. Provided that intraocular pressure is maintained at
satisfactory levels, many patients can then be placed on once daily therapy.
If necessary, concomitant treatment with miotics, epinephrine and/or carbonic
anhydrase inhibitors can be instituted. In order to prevent the active
substance(s) from being washed out when additional ophthalmic medication is
used, an interval of at least 10 minutes between each application is
recommended. The use of two topical beta-adrenergic agents is not
recommended.
Transfer from other topical beta-blocking agents: Discontinue use after a full
day of therapy and start treatment with Timolol Eye Drops the next day, with
one drop in each affected eye twice daily.
Transfer from a single antiglaucoma agent other than a topical beta-blocking
agent: Continue the agent and add one drop of Timolol Eye Drops in each
affected eye twice daily. On the following day, discontinue the previous agent
completely, and continue with Timolol Eye Drops.
Patients should be instructed to remove soft contact lenses before using
timolol.
Paediatric Population:
Due to limited data, Timolol could only be recommended for use in Primary
congenital and primary juvenile glaucoma for a transitional period while
decision is made on a surgical approach and in case of failed surgery while
awaiting further options.
Posology:
Clinicians should strongly evaluate the risks and benefits when considering
medical therapy with Timolol in paediatric patients. A detailed paediatric
history and examination to determine the presence of systemic abnormalities
should precede the use of Timolol.
No specific dosage recommendation can be given as there is only limited
clinical data (see also section 5.1). However, if benefit outweighs the risk, it is
recommended to use the lowest active agent concentration available once
daily. If IOP could not be sufficiently controlled, a careful up titration to a
maximum of two drops daily per affected eye has to be considered. If applied
twice daily, an interval of 12 hours should be preferred.
Furthermore the patients, especially neonates, should be strongly observed
after the first dose for one to two hours in the office and closely monitored for

ocular and systemic side effects until surgery is performed. With regard to
paediatric use, the 0.1% active agent concentration might already be sufficient.
Method of administration:
To limit potential adverse effects only one drop should be instilled per dosing
time. Systemic absorption of topically administered β-blockers can be reduced
by nasolacrimal occlusion and by keeping the eyes closed as long as possible
(e.g. for 3 - 5 minutes) after instillation of drops. See also section 4.4, 5.2.
Duration of treatment:
For a transient treatment in the paediatric population (see also section 4.2
“Paediatric Population”).

4.3.

Contraindications
Timolol Eye Drops is contraindicated in patients with:









4.4.

Cardiogenic shock;
Overt cardiac failure;
Second and third degree AV block not controlled with pace-maker;
Sinus bradycardia, sick sinus syndrome sino-atrial block;
Reactive airway disease including bronchial asthma or a history of
bronchial asthma;
Presence or history of severe chronic obstructive pulmonary disease;
Severe peripheral circulatory disturbances (Raynaud disease);
Hypersensitivity to the active substance, any of the excipients or other
beta-blocking agents.

Special warnings and precautions for use
Like other topically applied ophthalmic drugs, Timolol Eye Drops is absorbed
systemically. Due to beta-adrenergic component, timolol, the same types of
cardiovascular, pulmonary and other adverse reactions seen with systemic
beta-adrenergic blocking agents may occur. Incidence of systemic ADRs after
topical ophthalmic administration is lower than for systemic administration.
To reduce the systemic absorption, see 4.2.
Cardiac disorders:
In patients with cardiovascular diseases (e.g. coronary heart disease,
Prinzmetal's angina and cardiac failure) and hypotension therapy with betablockers should be critically assessed and the therapy with other active
substances should be considered. Patients with cardiovascular diseases should
be watched for signs of deterioration of these diseases and of adverse
reactions. Due to its negative effect on conduction time, beta-blockers should
only be given with caution to patients with first degree heart block.

Vascular disorders
Patients with severe peripheral circulatory disturbance/disorders (i.e. severe
forms of Raynaud’s disease or Raynaud’s syndrome) should be treated with
caution.
Respiratory disorders:
Respiratory reactions, including death due to bronchospasm in patients with
asthma have been reported following administration of some ophthalmic betablockers.
Timolol Eye Drops should be used with caution, in patients with
mild/moderate chronic obstructive pulmonary disease (COPD) and only if the
potential benefit outweighs the potential risk.
Hypoglycaemia/diabetes
Beta-blockers should be administered with caution in patients subject to
spontaneous hypoglycaemia or to patients with labile diabetes, as betablockers may mask the signs and symptoms of acute hypoglycaemia.
Beta-blockers may also mask the signs of hyperthyroidism.
Corneal diseases
Ophthalmic β-blockers may induce dryness of eyes. Patients with corneal
diseases should be treated with caution.
Other beta-blocking agents
The effect on intra-ocular pressure or the known effects of systemic betablockade may be potentiated when timolol eye drops is given to the patients
already receiving a systemic beta-blocking agent. The response of these
patients should be closely observed. The use of two topical beta-adrenergic
blocking agents is not recommended (see section 4.5).
Anaphylactic reactions
While taking beta-blockers, patients with history of atopy or a history of
severe anaphylactic reaction to a variety of allergens may be more reactive to
repeated challenge with such allergens and unresponsive to the usual dose of
adrenaline used to treat anaphylactic reactions.
Choroidal detachment
Choroidal detachment has been reported with administration of aqueous
suppressant therapy (e.g. timolol, acetazolamide) after filtration procedures.
Surgical anaesthesia
β-blocking ophthalmological preparations may block systemic β-agonist
effects e.g. of adrenaline. The anaesthesiologist should be informed when the
patient is receiving timolol.
This formulation of Timolol Eye Drops contains benzalkonium chloride as a
preservative which may be deposited in soft contact lenses. Hence, Timolol
Eye Drops should not be used while wearing these lenses. The lenses should

be removed before instillation of the drops and not reinserted earlier than 15
minutes after use.
When Timolol Eye Drops is used to reduce intraocular pressure in angleclosure glaucoma, it should be used with a miotic and not alone.
A reduction in ocular hypotensive response has been reported in some patients
following prolonged therapy with Timolol maleate eye drops.
Muscle weakness: Beta-adrenergic blockade has been reported to potentiate
muscle weakness consistent with certain myasthenic symptoms (e.g. diplopia,
ptosis, and generalised weakness). Timolol Eye Drops have been reported
rarely to increase muscle weakness in some patients with myasthenia gravis or
myasthenic symptoms.
Patients should be instructed to avoid allowing the tip of the dispensing
container to contact the eye or surrounding structures.
Patients should also be instructed that ocular solutions, if handled improperly
can become contaminated by common bacteria known to cause ocular
infections. Serious damage to the eye and subsequent loss of vision may result
from using contaminated solutions.
Patients should also be advised that if they develop any intercurrent ocular
condition (e.g. trauma, ocular surgery or infection), they should immediately
seek their physician's advice concerning the continued use of present multidose container.
There have been reports of bacterial keratitis associated with the use of topical
ophthalmic products.
Paediatric Population:
Timolol solutions should generally be used cautiously in young glaucoma
patients (see also section 5.2). It is important to notify the parents of potential
side effects so they can immediately discontinue the drug therapy. Signs to
look for are for example coughing and wheezing. Because of the possibility of
apnoea and Cheyne-Stokes breathing, the drug should be used with extreme
caution in neonates, infants and younger children. A portable apnoea monitor
may also be helpful for neonates on Timolol.

4.5.

Interaction with other medicinal products and other forms of interaction
No specific drug interaction studies have been performed with timolol.
There is a potential for additive effects resulting in hypotension and/or marked
bradycardia when ophthalmic beta-blockers solution is administered
concomitantly with oral calcium channel blockers, beta-adrenergic blocking

agents, antiarrhythmics (including amiodarone), digitalis glycosides,
parasympathomimetics, guanethidine.
Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has
been reported during combined treatment with CYP2D6 inhibitors (e.g.
quinidine, fluoxetine, paroxetine) and timolol.
Mydriasis resulting from concomitant use of ophthalmic beta-blockers and
adrenaline (epinephrine) has been reported occasionally.
Clonidine: increased risk of "rebound hypertension" on discontinuation of
clonidine.
Anaesthetic drugs: increased risk of myocardial depression and hypotension
due to blockage of cardiac response to reflex sympathetic stimuli.
Cimetidine, hydralazine, phenothiazines and alcohol: may increase plasma
level of timolol.

4.6.

Fertility, pregnancy and lactation
Pregnancy
There are no adequate data for the use of timolol in pregnant women. Timolol
should not be used during pregnancy unless clearly necessary.
To reduce the systemic absorption, see 4.2.
Epidemiological studies have not revealed malformative effects but show a
risk for intra uterine growth retardation when beta-blockers are administered
by the oral route. In addition, signs and symptoms of beta-blockade (e.g.
bradycardia, hypotension, respiratory distress and hypoglycaemia) have been
observed in the neonate when beta-blockers have been administered until
delivery. If Timolol Eye Drops is administered until delivery, the neonate
should be carefully monitored during the first days of life.
Lactation
Beta-blockers are excreted in breast milk. However, at therapeutic doses of
timolol in eye drops it is not likely that sufficient amounts would be present in
breast milk to produce clinical symptoms of beta-blockade in the infant. To
reduce the systemic absorption, see 4.2.

4.7

Effects on ability to drive and use machines
There are currently no data available on the effects of Timolol Eye Drops
0.5% on the ability to drive or use machinery. It has to be taken into account
that dizziness, fatigue, transient ocular irritation, blurred vision and
lacrimation may occur occasionally.

4.8

Undesirable effects

Like other topically applied ophthalmic drugs, timolol is absorbed into the systemic
circulation. This may cause similar undesirable effects as seen with systemic betablocking agents. Incidence of systemic ADRs after topical ophthalmic administration
is lower than for systemic administration. Listed adverse reactions include reactions
seen within the class of ophthalmic beta-blockers
Immune system disorders:
Systemic allergic reactions including angioedema, urticaria, localized and generalized
rash, pruritus, anaphylactic reaction.
Metabolism and nutrition disorders:
Hypoglycaemia.
Psychiatric disorders:
Insomnia, depression, nightmares, memory loss.
Nervous system disorders:
Syncope, cerebrovascular accident, cerebral ischemia, increases in signs and
symptoms of myasthenia gravis, dizziness, paraesthesia, and headache.
Eye disorders:
Signs and symptoms of ocular irritation (e.g. burning, stinging, itching, tearing,
redness), blepharitis, keratitis, blurred vision and choroidal detachment following
filtration surgery (see 4.4 Special warnings and special precautions for use),
conjunctivitis, decreased corneal sensitivity, dry eyes, corneal erosion ptosis, diplopia.
Cardiac disorders:
Bradycardia, chest pain, palpitations, oedema, arrhythmia, congestive heart failure,
atrioventricular block, cardiac arrest, cardiac failure.
Vascular disorders:
Hypotension, Raynaud's phenomenon, cold hands and feet, intermittent claudication.
Respiratory, thoracic, and mediastinal disorders:
Bronchospasm (predominantly in patients with pre-existing bronchospastic disease),
dyspnoea, cough, respiratory failure, nasal congestion.
Gastrointestinal disorders:
Dysgeusia, nausea, dyspepsia, diarrhoea, dry mouth, abdominal pain, vomiting.
Skin and subcutaneous tissue disorders:
Alopecia, psoriasiform rash or exacerbation of psoriasis, skin rash.
Musculoskeletal and connective tissue disorders:
Myalgia.

Reproductive system and breast disorders:
Sexual dysfunction, decreased libido.
General disorders and administration site conditions:
Asthenia/fatigue.
The following adverse events have been reported but a causal relationship to therapy
with timolol eye drops has not been established:Metabolism & nutrition disorders: anorexia
Psychiatric disorders: behavioural disorders including confusion, hallucination,
anxiety, disorientation, nervousness, somnolence, psychic disturbances.
Eye disorders: aphakic cystoids macular oedema
Cardiac disorders: angina pectoris aggravated
Vascular disorders: hypertension, pulmonary oedema
Gastrointestinal disorders: retroperitoneal fibrosis
Skin and subcutaneous tissue disorders: pemphigoid
Reproductive system and breast disorders: impotence
The following additional adverse events have been reported with oral timolol maleate
and may be considered as potential effects of ophthalmic timolol maleate:Blood & lymphatic system disorders: purpura non-thrombocytopenic
Metabolism & nutrition disorders: weight loss, hyperglycaemia
Nervous system disorders: vertigo
Psychiatric disorders: concentration impaired
Ear disorders: tinnitus
Vascular disorders: arterial insufficiency, vasodilation
Respiratory, thoracic, and mediastinal disorders: rales, bronchial obstruction,
Hepatobiliary disorders: hepatomegaly
Skin and subcutaneous tissue disorders: skin irritation, pigmentation abnormal,
sweating
Musculoskeletal & connective tissue disorders: pain in extremity, arthralgia
Renal and urinary disorders: dysuria
General disorders and administration site conditions: exercise tolerance decreased
In addition, the following additional adverse events have been reported with other
beta-adrenergic blocking agents and may be considered as potential effects of
ophthalmic timolol maleate:Immune system disorders: fever combined with general muscle aches, throat sore,
laryngospasm and respiratory distress.
Blood & lymphatic system disorders: agranulocytosis, thrombocytopenic purpura
Psychiatric disorders: catatonia, an acute reversible syndrome (disorientation, memory
loss, emotional lability, depressed level of consciousness, performance status
decreased).
Gastrointestinal disorders: mesenteric artery thrombosis, colitis ischaemic.
Reproductive system and breast disorders: Peyronie’s disease
There have been reports of a syndrome comprising psoriasiform skin rash,
conjunctivitis, otitis and sclerosing serositis attributed to the beta-adrenergic receptor
blocking agent, practolol. This syndrome has also been reported with timolol maleate.

Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is
important. It allows continued monitoring of the benefit/risk balance of the medicinal
product. Healthcare professionals are asked to report any suspected adverse reactions
via Yellow card scheme at www.mhra.gov.uk/yellowcard

4.9

Overdose
No specific data are available. Overdosage is unlikely to occur as one 5ml
bottle of Timolol Eye Drops 0.5% contains 12.5 mgs of Timolol maleate
compared with the usual adult oral dose of 20-60 mgs per day. However, in
the rare event that overdosage occurs the most common signs and symptoms to
be expected following overdosage with a beta-adrenergic receptor blocking
agent are symptomatic bradycardia, hypotension, bronchospasm, and acute
cardiac failure. If overdosage occurs, the following measures should be
considered:
1.

Gastric lavage, if ingested. Studies have shown that timolol cannot be
easily
removed by hemodialysis.

2

Symptomatic bradycardia: Atropine sulphate, 0.25 to 2mg
intravenously, should be used to induce vagal blockade. If bradycardia
persists, intravenous isoprenaline hydrochloride should be
administered cautiously. In refractory cases, the use of a cardiac
pacemaker may be considered.

3

Hypotension: A sympathomimetic pressor agent such as dopamine,
dobutamine or noradrenaline should be used. In refractory cases, the
use of glucagon has been reported to be useful.

4

Bronchospasm: Isoprenaline hydrochloride should be used.
Additional therapy with aminophylline may be considered.

5

Acute cardiac failure: conventional therapy with digitalis, diuretics
and oxygen should be instituted immediately. In refractory cases, the
use of intravenous aminophylline is suggested. This may be followed,
if necessary, by glucagon which has been reported to be useful.

6

Heart block (second or third degree): Isoprenaline hydrochloride or a
pacemaker should be used.

5.

PHARMACOLOGICAL PROPERTIES

5.1.

Pharmacodynamic properties
Timolol is a non-selective β-adrenergic blocker, which does not possess
significant intrinsic sympathomimetic or local anaesthetic (membranestabilising) activity. When applied topically in the eye, it reduces both
elevated and normal intraocular pressure by inhibiting the production of
aqueous humour.
Unlike miotics, Timolol reduces intraocular pressure with little or no effect on
pupil size or accommodation.
The onset of reduction in intraocular pressure following ocular administration
of timolol can be detected within 30 minutes after a single dose The
maximum effect usually occurs in one to three hours and significant lowering
of intraocular pressure can be maintained for as long as 24 hours following a
single dose.
If systemically absorbed, as is possible, Timolol maleate is capable of
producing beta-blockade elsewhere in the body with consequent systemic
effects (increased airway resistance, bradycardia, hypotension etc.)
Paediatric Population:
There is only very limited data available on the use of Timolol (0.25%, 0.5%
twice daily one drop) in the paediatric population for a treatment period up to
12 weeks. One small, double blinded, randomized, published clinical study
conducted on 105 children (n=71 on Timolol) aged 12 days – 5 years show to
some extent evidence, that Timolol in the indication primary congenital and
primary juvenile glaucoma is effective in short term treatment.

5.2.

Pharmacokinetic properties
Topical instillation of 50μl of a 0.5% solution of timolol to the rabbit eye
resulted in rapid appearance of timolol in the aqueous humour and to a much
lesser degree in the plasma. The concentration in the aqueous humour (mean
of 2.47μg/ml) peaked 30 minutes after instillation. The plasma concentration
(0.188 μg/ml) also peaked at this time.
Following topical instillation in humans, the timolol concentration in aqueous
humour was 8-100 ng/ml within the first hour while the mean plasma
concentration was approximately 1 ng/ml within the first few hours (compared
with plasma concentrations of 5-50 ng/ml seen with therapeutic doses of oral
timolol).
Paediatric Population:

As already confirmed by adult data, 80% of each eye drop passes through the
nasolacrimal system where it may be rapidly absorbed into the systemic
circulation via the nasal mucosa, conjunctiva, nasolacrimal duct, oropharynx
and gut, or the skin from tear overflow. Due to the fact that the blood volume
in children is smaller than that in adults a higher circulation concentration has
to be taken into account. In addition, neonates have immature metabolic
enzyme pathways and it may result in an increase in elimination half-life and
potentiating adverse events. Limited data show that plasma timolol levels in
children after 0.25% greatly exceed those in adults after 0.5%, especially in
infants and are presumed to increase the risk of side effects such as
bronchospasm and bradycardia.
5.3

Preclinical safety data
Acute Toxicity Studies: Data have been reported in a number of animal
species. Oral LD50 in the mouse and rat are 1137 mg/kg and 1028 mg/kg
respectively. Subcutaneous LD50 in the mouse and rat are 300 mg/kg and 381
mg/kg respectively.
Chronic Toxicity Studies: No adverse ocular effects were observed with
ophthalmic topical administration of timolol in rabbits and dogs in studies
lasting one and two years respectively. In studies with oral administration in
high doses in dogs and rats, bradycardia and weight increase in the heart,
kidneys and liver were observed adverse effects.
Carcinogenicity: In a life-time study in mice, timolol increased the incidence
of benign and malignant pulmonary tumors, benign uterine polyps and
mammary adenocarcinomas in female mice when administered orally at doses
of 500mg/kg per day, but not at 5 or 50 mg/kg per day. In a 2 year study in
rats, oral timolol increased the incidence of adrenal pheochromocytomas in
male rats at 300 mg/kg per day but not at 25 or 100 mg/kg per day.
Mutagenicity: Timolol was not shown to be mutagenic when tested in vivo
(mouse) in the micronucleus test and cytogenetic assay (at doses up to 800
mg/kg) and in vitro in a neoplastic cell transformation assay (up to 0.1 mg per
ml).
Reproduction and fertility: Reproduction and fertility studies in rats have
not shown that timolol causes any adverse effects on male or female fertility
when administered orally at doses of up to 125 times the maximum
recommended human oral dose of 30mg. Studies in rats have shown that
timolol at doses of up to 50mg/kg/day (50 times the maximum recommended
human oral dose) caused delayed foetal ossification; however there were no
adverse effects on post-natal development of offspring. Teratogenic studies in
mice and rabbits have not shown that timolol at doses of up to 50 mg/kg/day
causes foetal malformations. In mice, timolol at doses of 1000 mg/kg/day
(1000 times the maximum recommended human oral dose) was maternotoxic
and resulted in an increased incidence of foetal resorptions.

In rabbits, timolol at 100 mg/kg/day (100 times the maximum recommended
human oral dose) increased incidence of foetal resorptions but not
maternotoxicity.
Timolol maleate 0.25% eye drops have not been adequately studied in human
pregnancy. Although timolol eye drops may be absorbed systemically, daily
treatment with Timolol Eye Drops 0.25% (1 drop, twice daily in both eyes)
will not exceed 0.4mgs timolol compared with the oral therapeutic dose of 2060 mgs/day. However as a precautionary measure, it is recommended that
timolol should not be used in pregnancy, unless the potential benefit to the
pregnant woman exceeds the potential risk to the foetus.

6

PHARMACEUTICAL PARTICULARS

6.1

List of excipients
Benzalkonium chloride
Disodium edetate
Disodium phosphate dodecahydrate
Sodium dihydrogen phosphate dihydrate
Sodium chloride
Water for injection

6.2

Incompatibilities
Benzalkonium chloride may be deposited in soft contact lenses. These lenses
should therefore be removed before instillation of the eye drops and not
reinserted earlier than 15 minutes after use.

6.3

Shelf life
Unopened:
Opened:

6.4

24 months
4 weeks

Special precautions for storage

Do not store above 25oC
To avoid contamination do not touch dropper tip to any surface.

6.5

Nature and contents of container
Pack Type A
Low density polyethylene (LDPE) bottle and white coloured polystyrene spiked
screw cap closure.
Pack size: 5 ml
Pack Type B
Low density polyethylene (LDPE) bottle with LDPE dropper nozzle, white coloured
HDPE screw cap and tamper- evident LDPE dust cover.
Pack size: 5 ml

6.6

Special precautions for disposal
No special requirements.

7

MARKETING AUTHORISATION HOLDER
FDC International Ltd
Unit 6 Fulcrum 1,
Solent Way,
Whiteley,
Fareham,
Hampshire
PO15 7FE
UK

8.

MARKETING AUTHORISATION NUMBER
15872/0002

9

DATE OF FIRST AUTHORISATION/RENEWAL OF THE
AUTHORISATION
07/09/2005

10

DATE OF REVISION OF THE TEXT
24/12/2015

Expand view ⇕

Source: Medicines and Healthcare Products Regulatory Agency

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.

Hide